FORTITUDE
Brief description of study
Currently, there are no approved evidence-based medicines for the treatment of symptoms in patients with nHCM. In the absence of proven therapies for the treatment of symptomatic patients with nHCM, this study employs a randomized, placebo-controlled, parallel-group design evaluating ninerafaxstat added to the standard of care (SoC) to maintain clinical equipoise.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or